Pay in 4 interest-free payments of $6.26 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Cardio and light movement do not counteract muscle loss
GLP-1 RA use is associated with a greater but moderate reduction in HbA 1c and lower risk of DKA when compared with SGLT2i therapy
4 Discussion Current evidence strongly supports the efficacy of GLP-1 receptor agonists for inducing substantial weight loss, improving metabolic control, and reducing cardiovascular risk often surpassing the short-term effects of exercise alone ( Exercise and lifestyle interventions, while generally less potent for weight loss, provide unique and irreplaceable health benefits preserving skeletal muscle, improving cardiorespiratory fitness, enhancing psychological well-being, and lowering chronic disease risk ( Hybrid care models that integrate pharmacotherapy with behavioral support are emerging as the most promising framework for sustainable obesity and diabetes management ( Persistent challenges include the high cost and limited accessibility of GLP-1RAs, variable long-term adherence, and a lack of long-term data on sustainability, relapse rates, and overall health outcomes
DOI: 10.1038/s41366-026-02088-1,
